AMSBIO has launched two new biotinylated formats of the 10E4 Heparan Sulfate antibody (high and low biotin) along with a starter pack to allow scientists to test both formats at a reduced cost.Heparan Sulfate (HS) is a highly sulfated linear polysaccharide that is attached to a core protein to form HS Proteoglycans on the cell membrane or in the extracellular matrix. It is involved in important biological processes due to it displaying specific interactions with many biologically active proteins. In particular, HS has emerged as a key factor in infection by the SARS-CoV-2 virus,…
Cleveland, UK, 29th April 2021 / Sciad Newswire / Leading UK peptide and antibody producers, Cambridge Research Biochemicals (CRB) have today signed a new distribution agreement with Fluoroprobes, LLC (FPL) and Click Chemistry Tools (CCT) to add FPL and CCT’s generic fluorescent activated dyes and click chemistry enabled click-reactive dyes to their existing service portfolio. The distribution agreement grants CRB the rights to market and sell the generic and improved Alexa Fluor-based DISCOVERY® Dyes both as part of their custom services, and with their catalogue peptide (DISCOVERY®…
Research Triangle Park, NC, USA, Cambridge, UK, Irvine, Calif., and Amsterdam – 28 April 2021 – Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision oncology for breast cancer.
Under the terms of the agreement, Agendia will gain co-exclusive rights to distribute Inivata’s RaDaR® liquid biopsy assay for the detection of Minimal Residual Disease (MRD) and early detection of relapse in patients with breast cancer in North America and Europe, with the option of extending territories over time. It is expected…
NOTTINGHAM, UK – 27 April, 2021 – Life Science Newswire – Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider, has established a new office presence in South San Francisco’s biotech hub at Oyster Point, where it can better serve current and future clients on the US west coast.The new office presence comes in the wake of another year of impressive growth for the company, which has recently expanded operations at its headquarters in Nottingham, UK, as well as opening a second co-located integrated drug discovery site at the world-class research…
CAMBRIDGE, MA and SOMERSET, NJ – Apr 27, 2021 — AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
Catalent will provide process development and CGMP manufacturing of AavantiBio’s…
Cambridge, UK: 27th April 2021
One Nucleus, the not-for-profit Life Science membership group headquartered in Cambridge, has welcomed EY to its Partner Programme.
The group supports growing Life Science businesses through their life cycle, as they translate great science into better patient outcomes. This includes facilitating connections between compliance, tax, investment and international growth.
Tony Jones, CEO of One Nucleus commented: ‘We are delighted to welcome EY to the One Nucleus Partner Programme. We look forward to connecting our members with their expertise and platforms such as…
The United Kingdom has become a fully independent third country to the European Union. In this 32 page special report patent specialists Garreth Duncan and Jennifer O’Farrell shine a spotlight on the impact of Brexit on the pharmaceutical industry, focusing on the challenges ahead as well as areas of opportunity for the UK.
Implementing the trade agreement the UK has made with the EU, and working through the inevitable snags, is the next challenge facing the pharmaceutical industry. Coupled with the additional pressures of the Covid-19 pandemic, this represents a significant challenge, but…
Work is set to begin on the first phase of Birmingham Health Innovation Campus this Summer after planning permission was granted by Birmingham City Council.
The first phase will see the development of No.1 Birmingham Health Innovation Campus which will offer 133,000 sq ft of lab and office space purposely designed for health innovation and life sciences businesses, with a focus on those working in medtech, precision medicine, biopharma and digital healthcare.
The building will include the home of the University of Birmingham’s Precision Health Technologies Accelerator…
AMSBIO has launched a comprehensive range of cytosections that offer a verified, reproducible and renewable source of positive / negative controls where the expression of the target biomarker is confirmed for accuracy and specificity by an immunoassay.Researchers, antibody and assay developers as well as Immunohistochemistry (IHC) labs often find it difficult to find a reliable and verified source of positive / negative controls for their IHC experiments. This is especially important when they are developing new IHC protocols for novel targets whose expression pattern is not known…